liver fibrosis

[Scientific Reports] Scientists evaluated changes in urea cycle enzymes in non-alcoholic fatty liver disease (NAFLD) patients and in two preclinical animal models mimicking this entity. Seventeen liver specimens from NAFLD patients were included for immunohistochemistry and gene expression analysis.

[Pharmacological Research] Scientists found that fibroblast growth factor 18 was markedly upregulated in carbon tetrachloride-induced fibrotic mouse liver tissues and transforming growth factor β stimulated LX-2 cells.

[Scientific Reports] Scientists characterized circulating extracellular vesicles and provided supporting data on their potential use as novel surrogate biomarkers for primary sclerosing cholangitis.

[Axcella Therapeutics] Axcella Therapeutics announced that the US FDA has granted a Fast Track Designation to AXA1125 for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis.

[Oncogene] Scientists tested the potent inducers of CD4 T helper 1 responses, live-attenuated Listeria monocytogenes ∆actA/∆inlB strain as preventive/therapeutic vaccine candidate in liver fibrosis, HCC, and hepatic cholangiocarcinoma.

[Chemosphere] The authors demonstrated that mono-2-ethylhexyl phthalate (MEHP) exposure inhibited the expression of STAT5A by causing oxidative damage in BRL-3A hepatocytes, thus accelerating the expression of key molecules in fibrosis and promoting the occurrence of liver fibrosis.